文献速递眼底病与葡萄膜炎

注射后眼内炎消退后渗出性年龄相关性黄斑变性相对静止

RELATIVE QUIESCENCE OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION AFTER RESOLUTION OF POSTINJECTION ENDOPHTHALMITIS.
PubMed 文献 · Retina · 2020-01-01

这项回顾性研究评估了因玻璃体腔抗VEGF注射后发生眼内炎患者的渗出性年龄相关性黄斑变性治疗负担和病程变化。

要点

  • 眼内炎消退后33%患者12个月内无需重启抗VEGF治疗。
  • 重启治疗者注射频率在12和24个月分别下降32%和38%。
  • 首次OCT随访10例患者脉络膜新生血管活动静止,黄斑厚度无显著变化。

核心结论

  • 眼内炎消退与脉络膜新生血管活动降低及抗VEGF治疗负担减少相关。

研究设计与样本

  • 评估眼内炎治疗前后抗VEGF注射频率、脉络膜新生血管活动和视力。

主要发现

  • 7例(33%)患者在眼内炎后12个月因黄斑变性静止且无显著视力下降(P > 0.05)而未重启抗VEGF治疗。
  • 重启治疗者注射频率在眼内炎后12和24个月分别下降32%和38%(P < 0.05)。
  • 首次OCT随访时10例患者脉络膜新生血管活动静止,但黄斑厚度无显著变化(P > 0.05)。
  • 辅助玻璃体腔激素治疗、培养结果或脉络膜新生血管亚型对眼内炎后黄斑变性进展或治疗负担无显著影响。

关键数值与推荐

  • 7例(33%)患者眼内炎后12个月未重启抗VEGF治疗且无显著视力下降(P > 0.05)。
  • 重启治疗者注射频率在12和24个月分别下降32%和38%(P < 0.05)。
  • 10例患者首次OCT随访显示脉络膜新生血管活动静止,黄斑厚度无显著变化(P > 0.05)。

临床怎么用

  • 眼内炎消退后部分渗出性年龄相关性黄斑变性患者可进入静止期,可考虑延长抗VEGF治疗间隔或暂停治疗。
  • 重启抗VEGF治疗的患者注射频率可能降低,需个体化调整随访和治疗方案。

局限性

  • 未报告眼内炎具体治疗方案及长期随访结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate alterations in treatment burden and course of exudative age-related macular degeneration in patients who contracted endophthalmitis from intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections. METHODS: Retrospective study at the University of Pittsburgh Medical Center examining frequency of anti-VEGF injections, activity of choroidal neovascularization, and visual acuity before and after endophthalmitis treatment. RESULTS: Twenty-one patients meeting inclusion criteria were identified, of whom 7 (33%) patients did not restart anti-VEGF treatment 12 months after endophthalmitis because of quiescence of exudative age-related macular degeneration without significant visual acuity loss (P > 0.05). Patients who resumed anti-VEGF treatment exhibited 32% and 38% decreases in injection frequency by 12 and 24 months after endophthalmitis, respectively (P < 0.05). On first optical coherence tomography follow-up, 10 patients exhibited quiescence of choroidal neovascularization activity, although there were no measurable changes in macular thickness (P > 0.05). No differences in post-endophthalmitis exudative age-related macular degeneration progression or treatment burden were observed when factoring adjuvant intravitreal steroid therapy, culture results, nor choroidal neovascularization subtypes. CONCLUSION: Endophthalmitis resolution is associated with a decrease in choroidal neovascularization activity and a reduction of anti-VEGF treatment burden in patients with exudative age-related macular degeneration.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Arnett JJ, Brodowska K, Gallagher DS, et al. RELATIVE QUIESCENCE OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION AFTER RESOLUTION OF POSTINJECTION ENDOPHTHALMITIS. Retina. 2020. PMID: 31800459. doi:10.1097/IAE.0000000000002666

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。